Sofosbuvir plus ledipasvir is also more efficacious than sofosbuvir on its own, achieving up to a 98 per cent success rate in clinical trials.

To do this, we must ensure the legal framework supports innovations in treatment and that Higher Education is delivering the skills and the workforce needed to develop the treatments of tomorrow.